Effective PK/PD Translational Strategies to Enable a Successful Early Clinical Development

Time: 5:00 pm
day: Day Two


  • Defining the translational PK/PD considerations for ADC FIH starting dose prediction
  • Integrating nonclinical knowledge through computational modeling and simulations to inform Phase I design dose escalations.
  • Exploring translational PK/PD data to support model-informed clinical safety mitigation strategy, drug-drug interaction risks